Anaptysbio Stock Performance
| ANAB Stock | USD 21.18 0.15 0.70% |
On a scale of 0 to 100, AnaptysBio holds a performance score of 6. The firm shows a Beta (market volatility) of 0.44, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, AnaptysBio's returns are expected to increase less than the market. However, during the bear market, the loss of holding AnaptysBio is expected to be smaller as well. Please check AnaptysBio's mean deviation, standard deviation, treynor ratio, as well as the relationship between the downside deviation and total risk alpha , to make a quick decision on whether AnaptysBio's price patterns will revert.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in AnaptysBio are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Despite somewhat inconsistent basic indicators, AnaptysBio sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.70) | Five Day Return 3.93 | Year To Date Return 58.53 | Ten Year Return 24.59 | All Time Return 24.59 |
1 | Shareholders in AnaptysBio are in the red if they invested three years ago | 02/05/2025 |
2 | Acquisition by Daniel Faga of 107350 shares of AnaptysBio subject to Rule 16b-3 | 02/14/2025 |
3 | Anaptys Announces Participation in March Investor Conferences | 02/27/2025 |
4 | Acquisition by Lizzul Paul F. of 1500 shares of AnaptysBio at 18.5 subject to Rule 16b-3 | 03/18/2025 |
5 | Disposition of 5000 shares by Eric Loumeau of AnaptysBio at 14.02 subject to Rule 16b-3 | 03/19/2025 |
6 | SGS Achieves ISO 450012018 ANAB Accreditation in North America | 03/20/2025 |
7 | Disposition of 6000 shares by Eric Loumeau of AnaptysBio subject to Rule 16b-3 | 03/21/2025 |
8 | Crude Oil Gains 1 US Composite PMI Surges In March | 03/24/2025 |
9 | AnaptysBio to Buyback 75.00 million in Stock | 03/25/2025 |
10 | SMT Corp announces ANAB scope expansion for accredited AS6171 High Risk Level 2 testing | 04/07/2025 |
11 | Trexquant Investment LP Sells 37,152 Shares of AnaptysBio, Inc. - MarketBeat | 04/14/2025 |
12 | Acquisition by Ecor1 Capital, Llc of 65184 shares of AnaptysBio at 12.9182 subject to Rule 16b-3 | 04/28/2025 |
| Begin Period Cash Flow | 36 M |
AnaptysBio | Build AI portfolio with AnaptysBio Stock |
AnaptysBio Relative Risk vs. Return Landscape
If you would invest 1,742 in AnaptysBio on January 29, 2025 and sell it today you would earn a total of 376.00 from holding AnaptysBio or generate 21.58% return on investment over 90 days. AnaptysBio is currently generating 0.5051% in daily expected returns and assumes 6.5001% risk (volatility on return distribution) over the 90 days horizon. In different words, 58% of stocks are less volatile than AnaptysBio, and 90% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
AnaptysBio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for AnaptysBio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as AnaptysBio, and traders can use it to determine the average amount a AnaptysBio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0777
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ANAB | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.5 actual daily | 58 58% of assets are less volatile |
Expected Return
| 0.51 actual daily | 10 90% of assets have higher returns |
Risk-Adjusted Return
| 0.08 actual daily | 6 94% of assets perform better |
Based on monthly moving average AnaptysBio is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of AnaptysBio by adding it to a well-diversified portfolio.
AnaptysBio Fundamentals Growth
AnaptysBio Stock prices reflect investors' perceptions of the future prospects and financial health of AnaptysBio, and AnaptysBio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on AnaptysBio Stock performance.
| Return On Equity | -1.83 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (1.59) % | ||||
| Operating Margin | (0.22) % | ||||
| Current Valuation | 284.79 M | ||||
| Shares Outstanding | 30.67 M | ||||
| Price To Earning | 81.21 X | ||||
| Price To Book | 9.23 X | ||||
| Price To Sales | 7.17 X | ||||
| Revenue | 91.28 M | ||||
| Gross Profit | (72.56 M) | ||||
| EBITDA | (92.74 M) | ||||
| Net Income | (145.23 M) | ||||
| Cash And Equivalents | 442.15 M | ||||
| Cash Per Share | 15.66 X | ||||
| Total Debt | 16.04 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 22.79 X | ||||
| Book Value Per Share | 2.33 X | ||||
| Cash Flow From Operations | (135.34 M) | ||||
| Earnings Per Share | (5.12) X | ||||
| Market Capitalization | 654.12 M | ||||
| Total Asset | 483.83 M | ||||
| Retained Earnings | (759.33 M) | ||||
| Working Capital | 386.45 M | ||||
| Current Asset | 297.84 M | ||||
| Current Liabilities | 16.6 M | ||||
About AnaptysBio Performance
By analyzing AnaptysBio's fundamental ratios, stakeholders can gain valuable insights into AnaptysBio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if AnaptysBio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if AnaptysBio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.30) | (0.32) | |
| Return On Capital Employed | (0.26) | (0.28) | |
| Return On Assets | (0.30) | (0.32) | |
| Return On Equity | (2.05) | (2.15) |
Things to note about AnaptysBio performance evaluation
Checking the ongoing alerts about AnaptysBio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for AnaptysBio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| AnaptysBio is way too risky over 90 days horizon | |
| AnaptysBio appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 91.28 M. Net Loss for the year was (145.23 M) with loss before overhead, payroll, taxes, and interest of (72.56 M). | |
| AnaptysBio currently holds about 442.15 M in cash with (135.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.66. | |
| Over 96.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Acquisition by Ecor1 Capital, Llc of 65184 shares of AnaptysBio at 12.9182 subject to Rule 16b-3 |
- Analyzing AnaptysBio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether AnaptysBio's stock is overvalued or undervalued compared to its peers.
- Examining AnaptysBio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating AnaptysBio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of AnaptysBio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of AnaptysBio's stock. These opinions can provide insight into AnaptysBio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for AnaptysBio Stock analysis
When running AnaptysBio's price analysis, check to measure AnaptysBio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AnaptysBio is operating at the current time. Most of AnaptysBio's value examination focuses on studying past and present price action to predict the probability of AnaptysBio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AnaptysBio's price. Additionally, you may evaluate how the addition of AnaptysBio to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Stocks Directory Find actively traded stocks across global markets |